CDKL5 and craniodiaphyseal dysplasia: In particular, its efficacy and safety have not yet been evaluated in the context of mosaic loss of CDKL5, which represents the typical condition of most CDD patients who are heterozygous for mutations in the X-linked CDKL5 gene.